OPDP’s first warning letter of 2022 targets CytoDyn for COVID claims

Regulatory NewsRegulatory NewsAdvertising, Promotion and LabelingBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticals